Abstract 2047
Background
TSAs are common side effects among cancer pts undergoing chemotherapy and may lead to inadequate dietary intake and reduced quality of life. Here, we investigate the incidence of multiple components of self-reported TSAs and its etiological determinants in a homogeneous group of pts with stage II-III CC.
Methods
We used data collected in an ongoing observational study within the Prospective Dutch Colorectal Cancer Cohort, designed to study nutritional factors and oncological outcomes. Pts receive questionnaires on dietary intake by food-frequency questionnaire (past month average intake), dietary supplement use and TSAs at diagnosis (T0), and at 6, 12, 24 months post-diagnosis. Here, we selected pts with stage II-III CC, with completed T6 questionnaires and available clinical data.
Results
We included 87/468 pts for analysis (updated for ESMO) with a mean age 64.0±7.6 years, 70% male and 70% current/former smokers. Adjuvant chemotherapy (ACT), received by 52% of pts, consisted of CAPOX (90%), FOLFOX (5%), or CAP (5%) as initial regimen. TSAs were reported at T0 (4% of pts) and at T6 (32% of pts). TSA presence was significantly related to receiving ACT (RR 13.8, 95%CI: 3.5-54.3), but not to age, sex, education and smoking status. ACT treated pts more often reported a change in taste ability (49%, p < 0.001), change in taste perception (51%, p < 0.001), dry mouth (29%, p < 0.001), bad taste (38%, p < 0.001), and metallic taste (18%, p = 0.006), compared to pts who did not receive ACT. Pts with TSAs did not significantly differ from pts without TSAs in terms of caloric intake at T6 (p = 0.69). Caloric intake was low (no-TSA (n = 59) 1772 kCal and TSA (n = 28) 1809 kCal) and was below the ESPEN guidelines on nutrition in cancer patients for both groups.
Conclusions
TSAs are more prevalent in CC pts who received ACT compared to pts who did not, with taste more affected than smell. Pts had caloric intake below guideline recommendations at T6. The influence of TSAs on caloric intake appears to be limited when caloric intake is already insufficient. More pts, follow-up, and data on macronutrients and quality of life are needed to confirm and enrich these preliminary findings and ultimately help improve supportive care.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
University Medical Center Utrecht.
Funding
Province of Utrecht, The Netherlands.
Disclosure
B. Dorresteijn: Full / Part-time employment: Danone Nutricia Research. M. Jourdan: Full / Part-time employment: Danone Nutricia Research. All other authors have declared no conflicts of interest.
Resources from the same session
3317 - Circulating tumor DNA (ctDNA) analysis in patients (pts) with non-small cell lung cancer (NSCLC) treated with telisotuzumab vedotin (teliso-v), an antibody-drug conjugate targeting c-Met
Presenter: Rebecca Heist
Session: Poster Display session 1
Resources:
Abstract
3887 - First Real Life Data on Durvalumab after definitive concomitant ChemoRadiotherapy (cCRT) in unresectable Stage (St) III Non-Small Cell Lung Cancer (NSCLC) in France: Analysis of 591 patients (pts) enrolled in the French cohort (c) Temporary Authorization of Use (ATU)
Presenter: Virginie Avrillon
Session: Poster Display session 1
Resources:
Abstract
682 - EGFR Inhibitor Versus Chemotherapy as Adjuvant Treatment for Locally-advanced EGFR-mutant Non-Small Cell Lung Cancer
Presenter: Peng Xie
Session: Poster Display session 1
Resources:
Abstract
2509 - Afatinib in EGFR TKI-naïve patients with EGFR mutation-positive (EGFRm+) NSCLC: interim analysis of a Phase IIIb, multi-national, open-label study
Presenter: Filippo de Marinis
Session: Poster Display session 1
Resources:
Abstract
3300 - First-line ceritinib versus chemotherapy in patients (pts) with advanced ALK rearranged (ALK+) non-small cell lung cancer (NSCLC): ASCEND-4 Asian subgroup analysis
Presenter: Daniel SW Tan
Session: Poster Display session 1
Resources:
Abstract
2653 - A combined analysis of two Phase IIIb studies of afatinib in EGFR TKI-naïve patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC
Presenter: Filippo de Marinis
Session: Poster Display session 1
Resources:
Abstract
3663 - Impact of plasma EGFR mutation fractions on response to first generation tyrosine-kinase inhibitor in treatment of naïve non-small cell lung cancer patients
Presenter: Xiaohong Wang
Session: Poster Display session 1
Resources:
Abstract
5921 - Definition of an afatinib trough concentration threshold in the treatment of NSCLC
Presenter: Stephane Bouchet
Session: Poster Display session 1
Resources:
Abstract
2852 - A Phase Ib Trial of Neoadjuvant Chemoradiotherapy and Durvalumab(MEDI4736) for Potentially Resectable stage III Non-Small Cell Lung Cancer (NSCLC)
Presenter: Beung chul AHN
Session: Poster Display session 1
Resources:
Abstract
3273 - Low expression of Notch1 and combined Notch1/HES1 are associated with adverse survival factor for limited stage small cell lung cancer
Presenter: Jinsoo Lee
Session: Poster Display session 1
Resources:
Abstract